Regulus Therapeutics Inc.RGLS

時価総額
$3458.1万
PER
2012年
12月31日
2013年
12月31日
2014年
12月31日
2015年
12月31日
2016年
12月31日
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
Net loss-17-19-57-56-82-72-49-19-16-28-28
Depreciation and amortization expense11122321100
Gain on PPP Loan forgiveness---------1-
Stock-based compensation2371513852332
Amortization of premiums and accretion of discounts on investments, net--1-2-1-1-0-0---0
Other----1110000
Contracts and other receivables-0010-8-1-01-1-1-
Prepaid materials---41-0-0-0-1-0-
Prepaid expenses and other assets---01-2-10000
Accounts payable-01113-0-4-0-1-0-0
Accrued liabilities-0112-1-0-1-1-000
Accrued research and development expenses--------1-00
Accrued compensation1-010-0-0-00000
Operating lease right-of-use assets and liabilities, net---------0-0
Other liabilities--------2-100
Net cash used in operating activities-9-28--50-57-59-43-20-13-24-26
Payments to Acquire Short-Term Investments6272113786556----33
Sales and maturities of short-term investments3332851011017047---18
Purchases of property and equipment11111000-00
Net cash used in investing activities-30-41-213514470-0-0-15
Proceeds from Issuance of Private Placement-------401832-
Proceeds from Issuance of Common Stock6646860143021214
Proceeds from Stock Options Exercised0127000000-
Payments on financing leases-------000-
Net cash provided by financing activities7046-72143-34010544
Net (decrease) increase in cash, cash equivalents and restricted cash-------20-329-36
Interest paid------22110
Income taxes paid---------00
Paycheck Protection Program loan forgiveness---------1-
Noncash or Part Noncash Acquisition, Fixed Assets Acquired----------0